21 July 2017

Pfizer

2017 – London Family Planning Summit

In support of FP2020, Pfizer Inc. and a consortium of donors—including the Bill & Melinda Gates Foundation, the Children’s Investment Fund Foundation, the UK Department for International Development (DFID), the United States Agency for International Development (USAID), and UNFPA—are launching a public-private collaboration to broaden access to Sayana Press, Pfizer’s innovative injectable contraceptive.

Sayana Press is a three-month contraceptive in the all-in-one, single-use Uniject™ injection system developed by PATH and manufactured by Becton, Dickinson & Company. Sayana Press contains a reformulation of depo medroxyprogesterone acetate that allows it to be administered subcutaneously (subQ). The product’s design means that community health workers, pharmacists, and even women themselves can be trained to administer it (where approved by national health authorities). Sayana Press is available to qualified purchasers at a guaranteed price of US $0.85 per dose, a reduction from the previous price of US $1.00 per dose.

Sayana Press is currently being introduced, scaled-up, or piloted in more than 15 FP2020 countries, with Pfizer continuing to support additional country registrations. The donor consortium is supporting the collaboration with over US $270 million in investments between now and 2022.

2016

In connection with ongoing programs and partnerships, Pfizer commits to support the UN Secretary General’s Every Woman, Every Child objectives by helping to address health priorities in the following ways: infant immunization to help prevent pneumococcal disease; education, training and advocacy programs on women and children’s health; healthcare system capacity building; and creating sustainable commercial models for products addressing the needs of women and children in developing countries. Pfizer continues to support the prioritization of infant immunization to help prevent the pneumococcal disease by acting as a major supplier of vaccines to the Advanced Market Commitment (AMC) since 2010. Through Pfizer Foundation’s Women and Children’s Health Portfolio programs we are committing up to $10 million between 2016 through July 2017 to reduce key barriers in health care delivery for women and children with a focus on improving access to immunization and family planning products and services. Pfizer remains committed to expanding access to contraceptive options to women most in need through a collaboration with the Bill & Melinda Gates Foundation and the Children’s Investment Fund Foundation (CIFF) to help broaden access to Pfizer’s injectable contraceptive, Sayana® Press, for women most in need in 69 of the world’s poorest countries. Sayana® Press is currently registered with local regulatory authorities in more than 41 countries. Pfizer is also actively in the process of seeking regulatory approval in a number of other countries, and exploring opportunities to help bring the updated self-injection label to more women in need across the globe.

2014-Every Newborn Action Plan

Pfizer commits to advancing newborn and maternal health through research, development, and production of science- and biomedical-based innovations, and through partnerships aimed at helping build the capacity needed to facilitate access to care for mothers and newborns. To support the Every Newborn Action Plan, Pfizer’s commitment is tailored around skilled birthing attendants, post-natal care, family planning, and access to vaccines and medicines aimed at reducing newborn and infant morbidity and mortality.

Pfizer is working independently and with partners to focus on several critical areas of newborn and maternal health, including: promoting higher utilization of skilled birth attendants and post-natal care services; scaling up interventions that save newborn lives and enhance newborn care; expanding access to family planning through new technology, training, and research; protecting infants and young children against pneumococcal disease with innovative vaccine technology and supply chain improvements; and donating antibiotics and placebos to allow independent researchers to study the effect on childhood morbidity and mortality in children under the age of five.

2010

Pfizer commits through ongoing programs and partnerships to support the UN Secretary General’s Every Woman, Every Child objectives by helping address health priorities in the following areas: infant immunization for the prevention of pneumococcal disease; education, training and advocacy programs on maternal and infant health; development of intermittent preventative treatment for malaria in pregnant women; infant and young child nutrition; healthcare system capacity building; and sustainable commercial models for products addressing the needs of women and children in developing countries.

One of the primary ways Pfizer supports the health priority of infant immunization for the prevention of pneumococcal disease is by acting as a major supplier to the Advanced Market Commitment (AMC). In 2010, Pfizer entered into a 10-year agreement with UNICEF to provide up to 300 million doses of Prevenar 13 to infants and young children in the poorest countries of the world at a deeply discounted price. Other Pfizer initiatives include supporting the needs of women and children in developing countries by working with institutional buyers, which purchase medicines in bulk and distribute them to some of the world’s neediest patients; and training nurses who provide primary and secondary prevention services to women and children in disadvantaged populations.

Learn More.
·         Prevenar 13 introduced in over 140 countries of which 37 are Gavi-eligible countries
·         Some 40M babies with access to the vaccine of which 18 million in Gavi-eligible countries.
·         Over $300M invested in manufacturing capacity and new preservative multi-dose formulation
·         18 million babies potentially vaccinated against pneumococcal disease with a greater chance of surviving to their 5th birthday
·         Contributing to helping avert more than 500,000 under 5 deaths by 2015 and up to 1.5 million by 2020
·         33% reduction in infant mortality in Nicaragua two years after introduction of vaccine
·         Contributing to help prevent more than 70% of childhood pneumococcal disease in Africa with Prevenar 13